Cite
HARVARD Citation
von Pawel, J. et al. (2018). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer. Oncologist. pp. 654-e58. [Online].